19844
By Science News
Your article reports 86 heart attacks among 15,560 rosiglitazone (Avandia) users, versus 72 others in a control group of 12,283. A study coauthor then says that “after statistical adjustment, that yields a 43 percent higher risk of heart attacks among rosiglitazone users.” Simple arithmetic would seem to indicate it was the control group that had a slightly higher risk.
Vincent Fecher
San Antonio, Texas